Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences (NASDAQ: GILD) has wanted to be a leader in cancer treatment for awhile, and this week, it made a big splash into the indication when it announced the planned acquisition of Kite Pharma (NASDAQ: KITE), a company developing a new platform for cancer treatment called CAR-T.
In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Michael Douglass is joined by Todd Campbell to discuss Gilead's oncology merger and acquisition (M&A) strategy. Watch the video below to find out if these industry watchers give this deal a "thumbs up."
A full transcript follows the video.
Source: Fool.com
Gilead Sciences Inc Aktie
74,31 €
-1,09 %
Einseitige Zustimmung für Gilead Sciences Inc mit mehreren Buy- und keiner Sell-Einschätzung.
Das Kursziel von 85 € für Gilead Sciences Inc weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 74.31 € hin.
